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Advances in understanding of the immune system are
changing the way oncologists treat cancer. In recent
years, researchers have increasingly looked to harnessing
the patient’s immune system in the management of dif-
ficult to treat cancers. While such an approach was
once felt to be unattainable, a better understanding of
how the adaptive immune system works has allowed the
field of immuno-oncology to move to the clinic with
increasing success. This study’s objective was to assess
practicing oncologists’ familiarity with, and understand-
ing of, immuno-oncology concepts that will play an
important role in the care of patients with metastatic
cancer such as those with lung cancer.
An expert panel was convened to identify knowledge
gaps in the area of immuno-oncology. A series of 9 CME
activities are planned, 4 of which have been developed and
posted online. Interactivity questions allowed learners to
self-report their familiarity with and/or confidence in con-
cepts related to immuno-oncology. The outcomes survey
consisted of knowledge-based questions that examined
knowledge of the evidence-base surrounding immuno-
oncology. Confidentiality of survey respondents was main-
tained and responses were de-identified and aggregated
prior to all analyses.
A total of 469 of oncologist have participated in the
surveys. Overall, oncologists reported a lack of familiar-
ity and need for additional education in the areas of
immunology as well as implications for immuno-oncol-
ogy agents. Less than 15% of oncologists reported being
very familiar with the immune system while 72% of lear-
ners indicated a need for additional education on adap-
tive immune responses. In addition, only 7% and11% of
oncologists reported being very familiar with the con-
cepts of immune escape and check points, respectively.
Over 60% of oncologists reported little familiarity with
emerging immunotherapies for the treatment of meta-
static solid tumors, and a majority did not have a firm
understanding of how to assess a patient’s response. In
alignment with learners’ self-assessment, pre-education
testing indicated knowledge and practice gaps in under-
standing of T cell regulation as well as mechanisms of
immune escape, MOA of immune checkpoint inhibitors,
understanding of clinical efficacy data, and assessing
treatment response. Finally, initial analysis indicated that
oncologists’ participation in these CME activities had an
impact on their knowledge and competence.
This study identified knowledge, competency, and
practice gaps in the understanding and use of immune
checkpoint inhibitors in metastatic cancer. Further
assessment of oncologists’ responses after participating
in the remaining educational intervention set is planned
to demonstrate improvement in oncologists understand-
ing and clinical practice.
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